thiotepa / Generic mfg. - LARVOL DELTA

EFFICACY OF HIGH-DOSE THIOTEPA, RITUXIMAB, AND POMALIDOMIDE AS A SALVAGE REGIMEN FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (ICML 2025) - "The R-TP regimen demonstrated high efficacy and good tolerability in patients with R/R PCNS-DLBCL, offering a promising treatment option in this challenging population."

Clinical • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

FIRST-LINE R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PCNSL (ICML 2025) - "The HCT regimen involved thiotepa 250 mg/m2 on days -7 and -6, busulfan 3.2 mg/kg on days -5 and -4, cytarabine 2 g/m2 q12h on days -3 and -2. The R-MTO induction treatment has demonstrated notable efficacy in achieving higher response rate among pts with newly diagnosed PCNSL, with a manageable safety profile. This study is a Trial in Progress. Further related data will be presented at a later date."

Clinical • CNS Lymphoma • Lymphoma • Primary Central Nervous System Lymphoma • TP53

EFFICACY OF THIOTEPA-CONDITIONED AUTOLOGOUS TRANSPLANTATION IS INDEPENDENT OF RESPONSE TO HD-MTX-BASED INDUCTION IN PRIMARY CNS LYMPHOMA: EBMT SERIES OF 1545 PATIENTS (ICML 2025) - "HD-MTX-based induction included high-dose cytarabine in 1388 (90%) pts, TT in 1,018 (66%), and rituximab in 1,264 (82%). To the best of our knowledge, this is the most extensive series of PCNSL patients treated with consolidative HDC-ASCT in routine practice. Despite the limitations of a registry-based study, such as the lack of image review, this analysis demonstrates that TT-based conditioning regimens were associated with significantly better outcomes and showed similar survival in pts achieving CR and PR at the time of ASCT. Additional investigations are needed to corroborate the beneficial effect of ASCT in some pts in PD after induction"

Clinical • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

MATRix REGIMEN FOR NEWLY DIAGNOSED PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES, ARISING IN CNS (PCNS-LBCL) AND VITREORETINAL (PVR-LBCL): OUTCOME AND TOXICITY (ICML 2025) - "The introduction of MATRix regimen (high-dose methotrexate, high-dose cytarabine, thiotepa, rituximab) in subjects younger than 70 years improved outcome, reaching a 7-year OS and PFS up to 70%. MATRix regimen followed by ASCT has improved survival rates of patients suffering from PCNS-LBCL and PVR-LBCL. Nevertheless, toxicity remains a major limiting factor impacting the broad use of this protocol. Thus, guidelines focusing on the optimization of the administration of this regimen are required."

B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

SEVEN-YEAR FOLLOW-UP OF THE IELSG42 "MARIETTA" PHASE II TRIAL: DURABLE REMISSIONS FOLLOWING MATRix/RICE INDUCTION AND THIOTEPA AUTOGRAFT IN SECONDARY CNS LYMPHOMA (ICML 2025) - "Introduction: The primary analysis of the MARIETTA study, the largest prospective trial focusing on secondary CNS lymphoma (SCNSL), demonstrated the activity of multi-agent chemotherapy with MATRix (rituximab, methotrexate, cytarabine, and thiotepa) and RICE (rituximab, etoposide, ifosfamide, carboplatin) followed by carmustine/thiotepa (BCNU/TT)-ASCT. Long-term follow-up of the international MARIETTA study demonstrates durable remissions in pts with SCNSL able to proceed to BCNU/TT-ASCT. A more favourable outcome was seen in pts with de novo SCNSL or iso-CNS-R. Conversely, outcomes remain poor in pts who did not proceed to ASCT and those with synch-CNS-R."

Clinical • P2 data • Chronic Lymphocytic Leukemia • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

[18F]FDG PET/MRI FOR ASSESSING TREATMENT RESPONSE OF CNS LYMPHOMA: A PROSPECTIVE CASE SERIES (ICML 2025) - "Patients with newly diagnosed CNS lymphoma (primary or secondary) who were candidates for methotrexate-cytarabine-thiotepa-rituximab (MATRix) induction were included after informed consent. This study suggests [18F]FDG-PET/MRI may offer more accurate and timely evaluation of treatment response in CNS lymphoma. Longer follow-up and larger studies are necessary to explore the prognostic value of absent [18F]FDG uptake in residual lesions with mild MRI enhancement. Further research is needed to determine whether PET/MRI enhances confidence in confirming complete response by complementing conventional MRI in post-treatment assessment, potentially leading to more personalized treatment strategies and improved outcomes."

Clinical • FDG PET • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Primary Central Nervous System Lymphoma

EXTRANODAL LYMPHOMAS: IMPROVED OUTCOME THROUGH INTERNATIONAL COLLABORATIVE RESEARCH (ICML 2025) - "The IELSG19 study, the largest randomized study in MALT lymphomas, demonstrated that rituximab in combination with chlorambucil significantly improves progression-free and event-free survival, while also establishing an effective prognostic model for MALT lymphomas...The IELSG32 study then established a new therapeutic standard by showing that the addition of rituximab and thiotepa to methotrexate and cytarabine—the so-called MATRix regimen—enhanced treatment efficacy...Through a multidisciplinary approach and international reach, cooperative academic efforts can reshape clinical practice and improve outcomes for patients worldwide. Keyword: extranodal non-Hodgkin lymphoma"

B Cell Lymphoma • CNS Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

A NOVEL CONDITIONING REGIMEN WITH ALKYLATING AGENTS, VENETOCLAX, CYTARABINE, CLADRIBINE, AND DECITABINE (ADVANCED) FOR UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION IN ADVERSE-RISK ACUTE MYELOID LEUKEMIA PATIENTS (EHA 2025) - "Alkylating agents were administered on days -3 and -2 individually (busulfan 3.2 mg/kg (days -3 and/or -2) or thiotepa 5 mg/kg (day -3) + busulfan 3.2 mg/kg (day -2), or melphalan 100 mg/m2 (day -2) based on age, general status, and prior treatment (Figure 1)...GVHD prophylaxis consisted of cyclophosphamide 40 mg/kg (days +3 and +4), a calcineurin inhibitor (from day -1 up to day +60 - +90), and mycophenolate mofetil (from day 0 up to day +35) (Figure 1).We collected patients' and AML characteristics...The ELN 2022 adverse risk aberrations were MECOM rearrangement (1), MECOM rearrangement + TP53 mutation (1), BCR-ABL1 (1), and MDS-related mutations (6).Ponatinib and Gilteritinib were added in two cases with BCR-ABL1 and FLT3 mutations, respectively... The upfront alloSCT with ADVANCED conditioning demonstrates promissing early efficacy for newly diagnosed or R/R adverse-risk AML patients with active disease. The toxicity profile was manageable without unexpected..."

Clinical • Metastases • Acute Myelogenous Leukemia • Febrile Neutropenia • Graft versus Host Disease • Immunology • Infectious Disease • Neutropenia • Transplantation • ABL1 • BCR • FLT3 • MECOM • TP53

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Stanford University | N=40 ➔ 60

Enrollment change • Acute Myelogenous Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology • Transplantation • HLA-B • HLA-C • HLA-DRB1

F-BMT CONDITIONING REGIMEN IMPROVES THE EFFICACY AND SAFETY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TRANSFUSION-DEPENDENT THALASSEMIA: A SINGLE-ARM CLINICAL TRIAL (EHA 2025) - "The F-BMT conditioning regimen consisted of fludarabine (30 mg/m2 on days -7 to -2), busulfan (130 mg/m2 on day -7), thiotepa (250 mg/m2 on day -5), melphalan (100 mg/m2 on day -3), cyclophosphamide (25 mg/kg on days +3 and +4). For patients with haploidentical donors, following were given: porcine anti-human lymphocyte immunoglobulin (25 mg/kg on days -1 and +5) or antithymocyte globulin (2.5 mg/kg on day -1 and 2mg/kg on day +5), methotrexate (5 mg/m2 on day +5), mycophenolate mofetil ( from days +5 to +28) and cyclosporine (from day +5 for 12 months), ruxolitinib (from days +5 to +28)... This study strongly suggests the efficacy and safety of the F-BMT conditioning regimen followed by HSCT as a reduced-toxicity regimen in older TDT patients."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

A NOVEL HOMOZYGOUS OSM MUTATION: FROM BONE MARROW FAILURE TO MYELOID NEOPLASM, A REPORT OF THREE CASES. (EHA 2025) - "Underwent haploidentical HSCT conditioning with thiotepa, fludarabine, and busulfan...Her transfusion needs decreased, but platelet levels dropped, prompting dose adjustments and danazol addition with good response... Our patient initially presented with BMF and progressed to a myeloid neoplasm. Similar to other inherited BMF syndromes (e.g., ERCC6L2, MYSM1 mutations), OSM deficiency manifests with BMF, and evolves to hypoplastic MDS then MDS-EB, ultimately transforming into AML. Genetic abnormalities progress with age, from normal karyotype to translocations, monosomies, and eventually a complex karyotype."

Clinical • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • CD123 • ERCC6 • IL31RA • IL6 • LIFR • MYSM1 • OSMR

The Value of Thin Layer Cytology in Cancer Patients' Pericardial Effusions. (PubMed, Curr Oncol) - "Regarding the 53 cases with chemotherapy treatment, the cytologic examination of pericardial fluid showed a remarkable reduction in neoplastic burden after the third dose of cisplatin or thiotepa instilled into the pericardial cavity. It allows the examination of exfoliated cells from the pericardial fluid, providing crucial information for diagnosis, management, and monitoring the acute responsiveness to intrapericardial chemotherapy. Immunocytochemistry (IHC) can identify specific markers for various types of cancer, enabling a more accurate diagnosis and guiding further treatment decisions."

Journal • Bladder Cancer • Breast Cancer • Cardiovascular • Colon Adenocarcinoma • Colon Cancer • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Lung Cancer • Lymphoma • Melanoma • Oncology • Ovarian Cancer • Parotid Gland Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: AN ANALYSIS FROM THE EBMT LYMPHOMA WORKING PARTY (ICML 2025) - "The most frequently used conditioning regimen was a combination of Busulfan, Fludarabine, and Thiotepa (42%). Post-transplant cyclophosphamide was administered in 40% of patients... In this large registry-based cohort of patients with PCNSL undergoing allo-HSCT, our findings indicate that allo-HSCT is an effective treatment in a subset of patients. The stable RI beyond one year may suggest a potential for long-term disease control in approximately one third of transplanted patients."

CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS THERAPY IS EFFECTIVE IN SECONDARY CNS LYMPHOMA REFRACTORY TO HIGH-DOSE METHOTREXATE-BASED CHEMOTHERAPY (ICML 2025) - " 23 pts were referred to holding: 6 partial-brain irradiation, 4 intrathecal CHT, 2 polatuzumab vedotin, 5 ibrutinib, 1 HD-ifosfamide-based CHT, 2 MATRix regimen, 1 thiotepa-based ASCT, combinations of these strategies in 2...Only one pt experienced G3–4 CRS, all CRS cases were successfully treated with tocilizumab and steroids, anakinra was used in 2 cases... Varied presentation and high aggressivity of SCNSL impede the use of a uniform treatment for these pts. SCNSL refractory to HDMTX-based polyCHT can benefit significantly from a tailored multimodal holding based on the pt's history and extension of disease. CAR-T may be considered a good therapeutic option in SCNSL pts with good PS and responsive to holding therapy."

CAR T-Cell Therapy • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

PLACE-OF-CARE PRODUCED FRESH FORMULATION MB-CART19.1 CELL THERAPY FOR RELAPSED OR REFRACTORY CD19+ HEMATOLOGICAL MALIGNANCIES WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT (ICML 2025) - "From May 2022 to December 2024, nine ≥ 18-year-old patients (pts) with R/R CD19+ B-cell lymphoma or B acute lymphocytic leukaemia (B-ALL) with CNS involvement underwent leukapheresis followed by POC MB-CART19.1 production, fludarabine and cyclophosphamide lymphodepleting chemotherapy and subsequent administration of 1 × 106 cells/kg (fresh cells in 7 (78%) pts) as a single or split dose. Thiotepa was added as part of the lympodepletion regimen in 6 (67%) pts...One patient recovered after G-CSF and romiplostim, three after autologous, and one after allogeneic stem cell transplantation...However, a significant proportion of patients relapse, highlighting the need for additional therapeutic strategies. While acute toxicity was manageable, significant late immune effector cell-associated hematotoxicity required interventions including stem cell support."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ORELABRUTINIB PLUS SEMUSTINE, TEMOZOLOMIDE AND LENALIDOMIDE (BMeTL) REGIMEN WITH SEQUENTIAL MAINTENANCE TREATMENT IN ELDERLY OR FRAIL PATIENTS WITH CNSL: A PHASE II STUDY (ICML 2025) - "After 4 cycles of induction therapy, complete response (CR) and partial response (PR) pts received sequential MT regimen (methotrexate, 3 mg/m2, day 1; thiotepa, 20 mg/m2, day 2) for 2–4 cycles in a 21-day cycle. BMeTL regimen sequential maintenance treatment resulted in promising efficacy and safety for elderly/frail pts with PCNSL and SCNSL. Additional data will be reported later."

Clinical • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • MYD88

Allogeneic haematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study. (PubMed, Blood Adv) - "Conditioning regimens were predominantly treosulfan-based (59%; with thiotepa, 34%); other patients received busulfan-based (24%) or melphalan-based (17%) regimens. This worldwide study expand data on HSCT for STAT3-HIES to 41 patients. Despite significant pre-HSCT pulmonary morbidity, OS was high, and patients have improved skin and respiratory disease, though the impact on extra-immune manifestations appears limited."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Bronchiectasis • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Diseases • Oncology • Orthopedics • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Transplantation • CD34 • STAT3

SUBSTANTIAL REDUCTION IN CHRONIC GRAFT-VERSUS-HOST DISEASE AND ADEQUATE IMMUNE RECONSTITUTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN UNRELATED DONOR TRANSPLANTATION: A COMPARATIVE CASE-CONTROL STUDY (EHA 2025) - "Study group included 61 consecutive patients who underwent MUD-HCT between 01/2021 and 09/2024 for myeloid malignancies with PTCy (50mg/kg on days +3 and +4) in addition to tacrolimus/mycophenolate mofetil (MMF) as GvHD prophylaxis. Conditioning regimen was busulfan/fludarabine/thiotepa...There was no difference in the CIN of CMV viremia between the PTCy and the control group for patients who received letermovir prophylaxis (20.6% vs. 24.0%, respectively, p=0.73)... We implemented PTCy for GvHD prophylaxis in the context of MUD-HCT and compared its efficacy to conventional non-PTCy-based strategies. The use of PTCy was not linked to delayed immune reconstitution or increased risk of viral reactivation. Moreover, PTCy was associated with substantial reduction in the occurrence of chronic GvHD, which translated to improved GRFS."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Transplantation • CD4

EFFICACY AND SAFETY OF THE TBF/ATG/CYCLOPHOSPHAMIDE COMBINED CONDITIONING REGIMEN IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ELDERLY PATIENTS WITH HEMATOLOGIC DISORDERS: INTERIM ANALYSIS OF A SINGLE-CENTER, SINGLE-ARM, PROSPECTIVE PHASE 2 STUDY (EHA 2025) - "The TBF group regimen was as follows: Thiotepa 5 mg/kg/day on days -8 to -7; Busulfan 0.8 mg/kg/day on days -6 to -4; Fludarabine 50 mg/kg on days -6 to -2; and ATG 6-7.5 mg/kg/day on days -3 to -1. The TBFPTCY regimen for allogeneic hematopoietic stem cell transplantation in older AML patients warrants further exploration."

Clinical • P2 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cardiovascular • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Transplantation

THIOTEPA, BUSULFAN COMBINED WITH CYCLOPHOSPHAMIDE CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH-RISK MALIGNANT HEMATOLOGIC DISEASES (EHA 2025) - "Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation.With a median follow-up of 609 (243-954) days, the 1-year and estimated 2-year overall survival (OS) rates were 85.2% ± 6.8% and 76.5% ± 8.5%, respectively. The study suggests that thiotepa and busulfan-based conditioning may be a promising option for patients with high-risk hematologic diseases undergoing allo-HSCT."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Central Nervous System Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Oncology • Transplantation

TWO THIOTEPA BASED CONDITIONING REGIMENS FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PRIMARY OR ISOLATED SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE CENTRE EXPERIENCE (EHA 2025) - "Treatment involves Methotrexate based induction and consolidation with high dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). At our centre, we had previously used a conditioning regimen including Busulfan, Lomustine and Thiotepa (BLT) with a recent switch to Carmustine-Thiotepa (BCNU-TT), following a review of updated results of the IELSG32 trial... Consolidation with HDC-ASCT is associated with overall survival of approximately 60% in PCNSL. Although the small cohort size limits deriving significance, patients treated with BCNU-TT, which includes a higher median dose of thiotepa, showed a trend toward improved survival. Both regimens display an acceptable safety profile."

Clinical • CNS Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mucositis • Neutropenia • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation

ROLE OF BLOOD CYCLOSPORINE LEVEL DURING THE EARLY POST-TRANSPLANT PHASE IN THE RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE (EHA 2025) - "Background: Blood concentration of cyclosporine A (CsA) during the early post-transplant period may prevent the occurrence of severe graft-versus-host disease (GVHD) in patients undergoing allogeneic stem cell transplantation (allo-HSCT)...Conditioning regimen consisted on Busulfan iv- based in myeloid malignancies and TBI or thiotepa-based in lymphoid malignancies. Patients with aplastic anemia received anti thymocyte globulin (ATG) and cyclophosphamide +/- fludarabine...GVHD prophylaxis consisted of cyclosporine and short course of methotrexate +/- ATG... In our study, CsA levels in the early post-transplant period were not associated with a higher incidence of grade II-IV acute GVHD, possibly because CsA residual levels were optimal in the majority of patients. This finding supports the idea that strict monitoring of CsA during this phase may help prevent acute GVHD."

Post-transplantation • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Transplantation

A REAL-WORLD ANALYSIS OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: A SINGLE CENTER STUDY IN CHINA (EHA 2025) - "Polatuzumab vedotin, an anti-CD79b monoclonal antibody, when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), offers the benefits of more convenient administration and comparable safety to the R-CHOP regimen, while demonstrating reduced toxicity comparison to DA-EPOCH-R...Another patient attained CMR following R-ESHAP treatment for lymph node relapse, whereas one succumbed to CNS relapse despite receiving multiple therapies, including surgery, HD-MTX, BV, selinexor, and thiotepa.5 patients received targeted therapies... POLA-R-CHP shows potential as an efficient therapy for PMBCL. Its frontline application could enhance overall response rates while reducing treatment-related toxicity."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Renal Disease • Respiratory Diseases • CD79B

HIGH-DOSE THIOTEPA COMBINED WITH RITUXIMAB AND POMALIDOMIDE IS A PERFECT ALTERNATIVE CHEMOTHERAPY REGIMEN FOR RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA (EHA 2025) - "The R-TP regimen demonstrated high efficacy and good tolerability in patients with R/R PCNS-DLBCL, offering a promising treatment option in this challenging population."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

TREATING PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES, ARISING IN CENTRAL NERVOUS SYSTEM (PCNS-LBCL) AND VITREORETINAL (PVR-LBCL) BEYOND INDUCTION THERAPY: THE ROLE OF CONSOLIDATION AND MAINTENANCE THERAPY. (EHA 2025) - "The majority of patients (34/60) were treated with the R-MPV (Rituximab-Methotrexate- Procarbazine-Vincristine) regimen, 16 patients received MATRIX (Methotrexate- Cytarabine- Thiotepa- Rituximab), 5 received HD-MTX, 1 HD-MTX/HD-ARA-C (High Dose Cytarabine), 4 various other regimens and 1 declined treatment...Fourteen patients received maintenance therapy: Bruton tyrosine kinase inhibitors (n=9), lenalidomide (n=3), temozolamide (n=2)... Despite therapy improvement for PCNSL, the prognosis remains poor. Our data, in accordance with the literature, demonstrate that ASCT has a beneficial effect on overall survival. More importantly, maintenance therapy seems to offer greater advantage on survival."

Clinical • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma